AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects. The gene discussed is STAT3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.